Survodutide is an investigational dual agonist that pairs GLP-1 with glucagon, a hormone that raises blood sugar rather than lowering it. Putting that in a weight drug reads as an error. It's the whole design, and no regulator has approved it yet.
The short answer. Survodutide: It is investigational, and now in Phase 3. Boehringer Ingelheim and Zealand Pharma develop it, and no regulator has approved it.
- Phase 2 cut body weight about 19%. That was the top dose, over 46 weeks.
- The glucagon receptor is what separates it. That second arm, not the GLP-1 half, is why its data read differently from the rest.
- Liver disease may matter more than weight. The metabolic liver disease work could end up being the more important readout for this compound.
Survodutide is an investigational dual GLP-1/glucagon agonist. It is now in Phase 3. It comes from Boehringer Ingelheim and Zealand Pharma. Its Phase 2 obesity trial ran 46 weeks. At the top dose it cut body weight about 19%.
The glucagon arm is what sets it apart. It may also matter for the liver. The work there covers metabolic liver disease. That data may mean more to you than the weight data. Survodutide is approved nowhere.
The glucagon arm
Survodutide's place in the class is defined by which second receptor it picked. Tirzepatide added GIP to GLP-1. Survodutide added glucagon. Both are dual agonists. They are not doing the same thing.
Glucagon is usually cast as insulin's opponent, because it raises blood glucose. Adding it to a weight-loss drug looks backwards at first. Then you account for the other thing glucagon receptor activation does. It drives energy expenditure and hepatic fat oxidation. GLP-1 supplies appetite suppression. The glucagon arm adds an “energy out” component. A GLP-1/GIP dual agonist does not have that.
That is the same logic retatrutide uses, with one fewer receptor. Retatrutide is GIP plus GLP-1 plus glucagon. Survodutide is GLP-1 plus glucagon. We read the comparison as close to a controlled experiment on what GIP contributes. The triple-agonist mechanism covers the full picture.
What the trials show
The Phase 2 obesity trial ran 46 weeks. The design used dose escalation. It reported roughly 19% mean body-weight reduction at the top dose. That places survodutide above semaglutide. It sits around or slightly below tirzepatide.
Read that ordering carefully. A Phase 2 figure and a Phase 3 figure aren't directly comparable, and Phase 2 results systematically regress.
Survodutide's more interesting program may be the liver one. It has been studied in metabolic dysfunction-associated steatohepatitis. There the glucagon arm's effect on hepatic fat oxidation is direct, not incidental. We would expect a drug whose second receptor targets the liver to be well positioned for a liver indication.
The tolerability trade. Glucagon agonism buys energy expenditure. It generally carries a heavier gastrointestinal burden than GIP co-agonism. GIP co-agonism appears to soften GI effects. More mechanism, more side effects. That trade recurs across the class. It is the same one retatrutide makes at one receptor further out.
Where it stands
Survodutide is not approved anywhere. It's in Phase 3 for obesity, with parallel work in metabolic liver disease. It also isn't widely available as a research compound. Unlike retatrutide, it hasn't attracted a large grey market, largely because it's less searched-for and less hyped.
For how survodutide sits against everything else in the class, see our 2026 class comparison.
Frequently asked questions
What is survodutide?
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. It's investigational: Phase 3 for obesity, with additional work in metabolic liver disease.
How much weight does survodutide produce?
Survodutide cut body weight approximately 19% on average at the top dose, in its Phase 2 obesity trial over 46 weeks. That sits between tirzepatide and retatrutide in the class ordering. Bear in mind you're weighing a Phase 2 result against Phase 3 results, which isn't like for like.
How is survodutide different from tirzepatide?
Different second receptor. Tirzepatide pairs GLP-1 with GIP; survodutide pairs it with glucagon. GIP contributes insulin response and appears to soften GI tolerability; glucagon contributes energy expenditure and hepatic fat oxidation.
Is survodutide FDA approved?
No. Survodutide is in Phase 3 and has no approval anywhere.
What to know now
- It is investigational, and now in Phase 3. Boehringer Ingelheim and Zealand Pharma develop it, and no regulator has approved it.
- Phase 2 cut body weight about 19%. That was the top dose, over 46 weeks.
- The glucagon receptor is what separates it. That second arm, not the GLP-1 half, is why its data read differently from the rest.
- Liver disease may matter more than weight. The metabolic liver disease work could end up being the more important readout for this compound.
- The 19% figure comes from Phase 2. Phase 3 is still running, so treat that number as provisional rather than settled.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about Survodutide deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
Uncontrolled self-report: no controls, no blinding, no purity check. In the r/survodutide threads checked here, survodutide is usually not taken alone. It is added on top of tirzepatide to break a months-long stall, a combination one commenter joked about as "Ghetto reta!" The reports conflict. Some describe more energy, less food noise and weight loss restarting after a stall, and one wrote "Would recommend." Others are flat: one called it "a lot of hype," and another said it "helped a little, but it wasn't amazing." Fatigue and a new sweet tooth recur, though several posters report the opposite on energy. The largest losses described in these threads come from people enrolled in Boehringer trials, not from people buying it.
Where the community and the published record disagree. Across the 26 survodutide trials listed on ClinicalTrials.gov, survodutide is always given on its own, against placebo or against semaglutide in a separate arm. Not one adds it to tirzepatide. SYNCHRONIZE-1 randomized 726 adults to survodutide 3.6 mg, 6.0 mg or placebo, and its exclusion criteria bar "Treatment with any medication for the indication obesity within 3 months before screening." The threads verified here do the reverse: survodutide stacked on top of tirzepatide. The trials deliberately excluded the exact population posting about it, so there is no published result that measures what these users are doing. The members reporting the largest losses on survodutide alone all said they were in Boehringer trials rather than buying it.
“I’ve definitely noticed my brain LOVES sweets on Survo”
“Been on tirz for a year and 8 months. Max dose. Lost 100ish so far. Have been on a several month plateau.”
“Anyone currently Survo stacking and can speak to how it's going for you?”
“Wondering if anyone has experience with completely stopping Tirz and just moving forward with Survo only and can speak to that?”
“I would also love to hear about people who also started with survo and not another GLP.”
“Are you suffering through nausea and low energy for zero actual fat loss?”
“Treatment with any medication for the indication obesity within 3 months before screening.”
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Survodutide's Phase 2 weight figure is as summarised in the Melson pipeline review rather than read from the primary trial publication, and is reported here as approximate for that reason.